Extending indication of CDK 4/6 inhibitors in the adjuvant and neoadjuvant setting

Share :
Sorry, this item is currently unavailable.
Published: 26 Oct 2016
Views: 2489
Dr Sara Hurvitz - UCLA Medical Center, Santa Monica, USA

Dr Hurvitz discusses preclinical data for palbociclib, ribociclib and abemaciclib in the 'Coming of Age CDK 4/6 Inhibition' symposium at the ESMO 2016 conference.

Supported by a grant from Pfizer Inc.